Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846812 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13039962 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL2377101 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13043828 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13939546 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL9898209 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13043827 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL9896981 | 1.00 | GAA (0.64) | GAAL3MBTL1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL9897986 | 0.98 | GAA (0.62) | GAAL3MBTL1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL9898478 | 0.98 | GAA (0.62) | GAAL3MBTL1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| EP-2892880-B1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-9447039-B2 | Indole carboxamide derivatives and uses thereof | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| EP-2892880-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| WO-2014037900-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | GAA 1240/4885L3MBTL1 1650/4885MEN1 907/4885 |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | GAA 1294/4885L3MBTL1 1593/4885MEN1 871/4885 |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | GAA 1240/4885L3MBTL1 1650/4885MEN1 907/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | GAA 3729/4885L3MBTL1 3474/4885MEN1 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.